Login to Your Account



Mesoblast Picks Up Lagging Stem Cell Franchise from Osiris

By Catherine Shaffer
Staff Writer

Friday, October 11, 2013
Osiris Therapeutics Inc. will sell its culture-expanded mesenchymal stem cell (ceMSC) business, including Prochymal, to Mesoblast Ltd. for up to $100 million including up-front and milestone payments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription